MarketLens
Sign Up

Has Innoviva Successfully Pivoted Beyond its Royalty Roots

8 months ago
SHARE THIS ON:

Has Innoviva Successfully Pivoted Beyond its Royalty Roots

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 months ago

Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot

Novavax shifted its business model from COVID-19 vaccine focus to a partnership-driven approach centered on its Matrix-M adjuvant technology, with near-term catalysts including Sanofi's NUVAXOVID roll...
Stock News•2 months ago

Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform

Trevi Therapeutics is advancing Haduvio for IPF-related chronic cough after positive Phase II data, with pivotal trials ongoing and expansion into non-IPF ILD and refractory chronic cough. Its special...
Stock News•2 months ago

Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic

Innoviva's royalty revenue is declining as GSK royalties face pressure, but new therapeutic products are ramping up. The company is transitioning to a diversified healthcare model, with a probability-...

Breaking News

View All →

Top Headlines

View More →
Stock News•26 minutes ago

Google parent Alphabet suffers nearly $500B Wall Street wipeout amid AI spending fears

Stock News•53 minutes ago

Amazon the Latest Mag 7 to Miss Q3 Estimates

Stock News•1 hour ago

20 Years of S&P 500 History Show: This Simple Strategy Is Only 8.3% Less Than "Perfect"

Stock News•1 hour ago

Microsoft Q1: Capex Shouldn't Scare You Due To Free Cash Flow

Stock News•1 hour ago

Microsoft Took The Balanced Approach To AI - Now It's The King